Tissue plasminogen activator and plasminogen activator inhibitor 1 in obese and lean patients with polycystic ovary syndrome
2010 (English)In: Gynecological Endocrinology, ISSN 0951-3590, E-ISSN 1473-0766, Vol. 26, no 10, 743-748 p.Article in journal (Refereed) Published
OBJECTIVE: Disturbances in the fibrinolytic system are predictors of future cardiovascular events. The aim of this study was to compare plasminogen activator inhibitor 1 (PAI-1) activity and tissue plasminogen activator (tPA) mass concentration between patients with polycystic ovary syndrome (PCOS) and control subjects.
DESIGN: One hundred thirty-five patients with PCOS (lean and obese) and 81 healthy controls were recruited for the study. Blood samples for PAI-1 activity and tPA mass were collected together with anthropometric measures.
RESULTS: Obese patients with PCOS displayed increased tPA mass concentration in comparison with controls (p <0.05), and this finding was consistent regardless of whether patients displayed signs of hyperandrogenism or not. When hyperandrogenism was introduced as a prerequisite for the PCOS diagnosis, obese patients with PCOS displayed increased PAI-1 activity as well, p <0.05. Lean patients with PCOS did not differ in terms of PAI-1 activity or tPA mass concentration in comparison to controls.
CONCLUSION: Obese women with PCOS have impaired fibrinolysis, in particular if they also display objective biochemical markers of hyperandrogenism.
Place, publisher, year, edition, pages
2010. Vol. 26, no 10, 743-748 p.
Polycystic ovary syndrome, PAI-1, tPA, obesity, free androgen index
Obstetrics, Gynecology and Reproductive Medicine
Research subject Obstetrics and Gynaecology
IdentifiersURN: urn:nbn:se:umu:diva-36927DOI: 10.3109/09513590.2010.487592ISI: 000282887300009PubMedID: 20500107OAI: oai:DiVA.org:umu-36927DiVA: diva2:356850